The Membranous Glomerulonephritis drugs in development market research report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Membranous Glomerulonephritis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Membranous Glomerulonephritis and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Membranous Glomerulonephritis by 18 companies/universities/institutes. The top development phase for Membranous Glomerulonephritis is phase ii with five drugs in that stage. The Membranous Glomerulonephritis pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Membranous Glomerulonephritis pipeline products market are: Shanghai Pharmaceutical Group, Jiangsu Hansoh Pharmaceutical Group and Haisco Pharmaceutical Group.

The key targets in the Membranous Glomerulonephritis pipeline products market include B Lymphocyte Antigen CD20, B Lymphocyte Antigen CD19, and ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1.

The key mechanisms of action in the Membranous Glomerulonephritis pipeline product include B Lymphocyte Antigen CD20 Inhibitor with two drugs in Phase III. The Membranous Glomerulonephritis pipeline products include six routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Membranous Glomerulonephritis pipeline products market including Monoclonal Antibody, and Gene-Modified Cell Therapy.

Membranous Glomerulonephritis overview

Membranous Glomerulonephritis or membranous nephropathy is an autoimmune glomerular disease that affects the functioning of kidneys. Idiopathic and commonly seen in adults. It leads to nephrotic syndrome characterized by edema, proteinuria, frothy urine. Secondary causes of glomerulonephritis is NSAIDs induced, HBV, SLE, cancer and other infectious diseases. Edema, weight gain, fatigue, proteinuria are the symptoms and is diagnosed by analyzing protein levels in urine, biopsy of kidney, blood picture, GFR rate. Fluid restriction if edema is seen and low salt diet is recommended. If cause is autoimmune immunosuppressants are prescribed and antibiotics and angiotensin receptor blockers (ARBs) and anticoagulant therapy.

For a complete picture of Membranous Glomerulonephritis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.